Literature DB >> 18685613

Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.

M Klier1, N Anastasov, A Hermann, T Meindl, D Angermeier, M Raffeld, F Fend, L Quintanilla-Martinez.   

Abstract

Cyclin D1 overexpression is the hallmark of mantle cell lymphoma (MCL). However, the importance of cyclin D1 in the maintenance and progression of the disease remains to be defined. The aim of this study was to elucidate the role of cyclin D1 overexpression using an efficient cyclin D1-shRNA and a lentiviral system in well-characterized MCL cell lines. Surprisingly, the knockdown of cyclin D1 led to a moderate retardation in growth, without induction of apoptosis. The cyclin D1-shRNA-transduced MCL cells showed a 15% shift from S phase to G(1) phase of the cell cycle, a weak induction of p27(Kip1), decreased Rb (Ser807/811) phosphorylation, and a consistent upregulation of cyclin D2 mRNA and protein expression. However, double knockdown of cyclins D1 and D2 did not intensify the effects observed with cyclin D1 knockdown alone. These data suggest that the moderate effects of cyclin D1 downregulation on survival and proliferation are likely the result of compensatory cyclin-independent mechanisms governing proliferation or alternatively, secondary genetic events that make cyclin D1 dispensable. These findings have important implications for MCL therapy, as strategies targeting only cyclin D1 function might be hampered by compensatory regulatory mechanisms, resulting in a low probability of treatment response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685613     DOI: 10.1038/leu.2008.213

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  38 in total

1.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma.

Authors:  Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-24       Impact factor: 4.064

2.  All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma.

Authors:  Amareshwar T K Singh; Andrew M Evens; Reilly J Anderson; Jennifer A Beckstead; Natesan Sankar; Antonella Sassano; Savita Bhalla; Shuo Yang; Leonidas C Platanias; Trudy M Forte; Robert O Ryan; Leo I Gordon
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

3.  Interleukin 22 signaling promotes cell growth in mantle cell lymphoma.

Authors:  Pascal Gelebart; Zoulika Zak; Jennifer Dien-Bard; Mona Anand; Raymond Lai
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

4.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 5.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

6.  The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies.

Authors:  Guergana Tchakarska; Anne Le Lan-Leguen; Lucile Roth; Brigitte Sola
Journal:  Haematologica       Date:  2009-08-13       Impact factor: 9.941

7.  Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.

Authors:  Paolo Conrotto; Ulrika Andréasson; Venera Kuci; Carl A K Borrebaeck; Sara Ek
Journal:  Mol Oncol       Date:  2011-08-22       Impact factor: 6.603

8.  C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.

Authors:  Natasa Anastasov; Irina Bonzheim; Martina Rudelius; Margit Klier; Therese Dau; Daniela Angermeier; Justus Duyster; Stefania Pittaluga; Falko Fend; Mark Raffeld; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR.

Authors:  Leticia Quintanilla-Martinez; Julia Slotta-Huspenina; Ina Koch; Margit Klier; Eric D Hsi; Laurence de Leval; Wolfram Klapper; Stefan Gesk; Reiner Siebert; Falko Fend
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.

Authors:  Ryan A Metcalf; Shuchun Zhao; Matthew W Anderson; Zhi Shun Lu; Ilana Galperin; Robert J Marinelli; Athena M Cherry; Izidore S Lossos; Yasodha Natkunam
Journal:  Mod Pathol       Date:  2010-01-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.